



UNIVERSITAT DE BARCELONA



Divisi3n de Ci3ncias de la Salut  
Facultad de Medicina

**EL COMPLEJO FACTOR VIIa - FACTOR TISULAR Y SU PAPEL  
COMPENSATORIO EN LAS DISFUNCIONES HEMOSTÁTICAS**

Tesis presentada por Raúl Tonda Hernández, licenciado en Biología por la Universidad de Barcelona para optar al grado de Doctor.

Tesis dirigida por el Dr. **GINÉS ESCOLAR ALBALADEJO** y la Dra. **ANA MARÍA GALÁN SILVO**.

Barcelona, Enero 2007



## **7. BIBLIOGRAFÍA**



Aarts PA, van den Broek SA, Prins GW, Kuiken GD, Sixma JJ, Heethaar RM. Blood platelets are concentrated near the wall and red blood cells, in the center in flowing blood. *Arteriosclerosis* 1988; 8:819-824.

Andrews RK, Shen Y, Gardiner EE, Dong JF, Lopez JA, Berndt MC. The glycoprotein Ib-IX-V complex in platelet adhesion and signaling. *Thromb Haemost* 1999; 82(2):357-364.

Bach RR. Tissue factor encryption. *Arterioscler Thromb Vasc Biol* 2006; 26(3):456-461.

Balasubramanian V, Grabowski E, Bini A, Nemerson Y. Platelets, circulating tissue factor, and fibrin colocalize in ex vivo thrombi: real-time fluorescence images of thrombus formation and propagation under defined flow conditions. *Blood* 2002; 100(8):2787-2792.

Barnes C, Blanchette V, Canning P, Carcao M. Recombinant FVIIa in the management of intracerebral haemorrhage in severe thrombocytopenia unresponsive to platelet-enhancing treatment. *Transfus Med* 2005; 15(2):145-150.

Baumgartner HR. Platelet interaction with collagen fibrils in flowing blood. Reaction of human platelet with  $\alpha$ -chymotrypsin digested subendothelium. *Thromb Haemost* 1977; 37:1-15.

Baumgartner HR, Turitto V, Weiss HJ. Effect of shear rate on platelet interaction with subendothelium in citrated and native blood. II. Relationships among platelet adhesion, thrombus dimensions, and fibrin formation. *J Lab Clin Med* 1980; 95:208-21.

Biro E, Sturk-Maquelin KN, Vogel GM, Meuleman DG, Smit MJ, Hack CE et al. Human cell-derived microparticles promote thrombus formation in vivo in a tissue factor-dependent manner. *J Thromb Haemost* 2003; 1(12):2561-2568.

Bogdanov VY, Balasubramanian V, Hathcock J, Vele O, Lieb M, Nemerson Y. Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein. *Nat Med* 2003; 9(4):458-462.

Brummel KE, Paradis SG, Butenas S, Mann KG. Thrombin functions during tissue factor-induced blood coagulation. *Blood* 2002; 100:148-152.

Conde I, Shrimpton CN, Thiagarajan P, Lopez JA. Tissue Factor-bearing microparticles arise from monocyte lipid rafts and can fuse with activated platelets, consolidating all of the membrane-bound coagulation reactions on the platelet surface. XIX Congress of the ISTH; Birmingham (UK) 03 Jul 15.

Davidson CJ, Tuddenham EG, McVey JH. 450 million years of hemostasis. *J Thromb Haemost* 2003; 1(7):1487-1494.

de Groot PG, Ottenhof Rovers M, van Mourik JA, Sixma JJ. Evidence that the primary binding site of von Willebrand factor that mediates platelet adhesion on subendothelium is not collagen. *J Clin Invest* 1988; 82:65-73.

Escolar G, Garrido M, Mazzara R, Castillo R, Ordinas A. Experimental basis for the use of red cell transfusion in the management of anemic-thrombocytopenic patients. *Transfusion* 1988; 28(5):406-411.

Escolar G, Galan AM, Mazzara R, Castillo R, Ordinas A. Measurement of platelet interactions with subendothelial substrata: relevance to transfusion medicine. *Transfus Med Rev* 2001; 15(2):144-156.

Falati S, Gross P, Merrill-Skoloff G, Furie BC, Furie B. Real-time in vivo imaging of platelets, tissue factor and fibrin during arterial thrombus formation in the mouse. *Nat Med* 2002; 8(10):1175-1181.

Falati S, Liu Q, Gross P, Merrill-Skoloff G, Chou J, Vandendries E et al. Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin. *J Exp Med* 2003; 197(11):1585-1598.

Galan AM, Tonda R, Altisent C, Maragall S, Ordinas A, Escolar G. Recombinant factor VIIa (Novoseven) restores deficient coagulation: experience from an ex vivo model. *Semin Hematol* 2001; 38(4 Suppl 12):10-14.

Galan AM, Tonda R, Pino M, Reverter JC, Ordinas A, Escolar G. Increased local procoagulant action: a mechanism contributing to the favorable hemostatic effect of recombinant FVIIa in PLT disorders. *Transfusion* 2003; 43(7):885-892.

Giesen PL, Rauch U, Bohrmann B, Kling D, Roque M, Fallon JT et al. Blood-borne tissue factor: another view of thrombosis. *Proc Natl Acad Sci U S A* 1999; 96(5):2311-2315.

Hathcock JJ, Nemerson Y. Platelet deposition inhibits tissue factor activity: in vitro clots are impermeable to factor Xa. *Blood* 2004; 104(1):123-127.

Hedner U. Factor VIIa in the treatment of haemophilia. *Blood Coagul Fibrinolysis* 1990; 1(3):307-317.

Hedner U, Glazer S. Management of hemophilia patients with inhibitors. *Hematol Oncol Clin North Am* 1992; 6(5):1035-1046.

Hedner U, Ingerslev J. Clinical use of recombinant FVIIa (rFVIIa). *Transfus Sci* 1998; 19(2):163-176.

Hedner U. NovoSeven (R) as a universal haemostatic agent. *Blood Coagulation & Fibrinolysis* 2000a; 11:S107-S111.

Hedner U. NovoSeven as a universal haemostatic agent. *Blood Coagul Fibrinolysis* 2000b; 11 Suppl 1:S107-S111.

Hirsh J, O'Donnell M, Weitz JI. New anticoagulants. *Blood* 2005; 105(2):453-463.

Hoffman M, Monroe DM, III. A cell-based model of hemostasis. *Thromb Haemost* 2001; 85(6):958-965.

Hoffman M, Monroe D. The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis. *Dis Mon* 2003; 49(1):14-21.

Key NS, Bach RR. Tissue factor as a therapeutic target. *Thromb Haemost* 2001; 85(3):375-376.

Kjalke M, Monroe DM, Hoffman M, Oliver JA, Ezban M, Roberts HR. Active site-inactivated factors VIIa, Xa, and IXa inhibit individual steps in a cell-based model of tissue factor-initiated coagulation. *Thromb Haemost* 1998; 80(4):578-584.

Kristensen J, Killander A, Hippe E, Helleberg C, Ellegard J, Holm M et al. Clinical experience with recombinant factor VIIa in patients with thrombocytopenia. *Haemostasis* 1996; 26 Suppl 1:159-164.

Levi MM, Vink R, de Jonge E. Management of bleeding disorders by prohemostatic therapy. *Int J Hematol* 2002; 76 Suppl 2:139-144.

Lisman T, Leebeek FW, Mosnier LO, Bouma BN, Meijers JC, Janssen HL et al. Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis. *Gastroenterology* 2001; 121(1):131-139.

Lisman T, Leebeek FW, Meijer K, van der MJ, Nieuwenhuis HK, De Groot PG. Recombinant factor VIIa improves clot formation but not fibrolytic potential in patients with cirrhosis and during liver transplantation. *Hepatology* 2002; 35(3):616-621.

Lisman T, Mosnier LO, Lambert T, Mauser-Bunschoten EP, Meijers JCM, Nieuwenhuis HK et al. Inhibition of fibrinolysis by recombinant factor VIIa in plasma from patients with severe hemophilia A. *Blood* 2003; 99:175-179.

Lisman T, Adelmeijer J, DE Groot PG, Janssen HL, Leebeek FW. No evidence for an intrinsic platelet defect in patients with liver cirrhosis - studies under flow conditions. *J Thromb Haemost* 2006; 4(9):2070-2072.

Lopez-Vilchez I, Escolar G, Diaz-Ricart M, Fuste B, Galan AM, White JG. Tissue factor enriched vesicles are taken up by platelets and induce platelet aggregation in the presence of factor VIIa. *Thrombosis and Haemostasis*. In press.

Macfarlane RG. An enzyme cascade in the blood clotting mechanism, and its function as a biochemical amplifier. *Nature* 1964; 202:498-9.

Mackman N. Role of tissue factor in hemostasis and thrombosis. *Blood Cells Mol Dis* 2006; 36(2):104-107.

Mackman N, Morrissey JH, Fowler B, Edgington TS. Complete sequence of the human tissue factor gene, a highly regulated cellular receptor that initiates the coagulation protease cascade. *Biochemistry* 1989; 28(4):1755-1762.

Mann KG. The challenge of regulating anticoagulant drugs: focus on warfarin. *Am Heart J* 2005; 149(1 Suppl):S36-S42.

Mann KG, Brummel K, Butenas S. What is all that thrombin for? *J Thromb Haemost* 2003; 1(7):1504-1514.

Martin DM, Boys CW, Ruf W. Tissue factor: molecular recognition and cofactor function. *FASEB J* 1995; 9(10):852-859.



Martinowitz U, Kenet G, Lubetski A, Luboshitz J, Segal E. Possible role of recombinant activated factor VII (rFVIIa) in the control of hemorrhage associated with massive trauma. *Can J Anaesth* 2002; 49(10):S15-S20.

Monroe DM, Hoffman M, Oliver JA, Roberts HR. Platelet activity of high-dose factor VIIa is independent of tissue factor. *British Journal of Haematology* 1997; 99:542-547.

Morel O, Toti F, Hugel B, Freyssinet JM. Cellular microparticles: a disseminated storage pool of bioactive vascular effectors. *Curr Opin Hematol* 2004; 11(3):156-164.

Nemerson Y, Pitlick FA. The tissue factor pathway of blood coagulation. *Prog Hemost Thromb* 1972; 1:1-37.

Nurden AT, Pico M, Fournier D, Jallu V, Lacaze D, Hourdille P. Glanzmann's Thrombasthenia - A General Introduction with Comments on Specific Cases. *Platelet Immunology : Fundamental and Clinical Aspects* 1991; 206:139-151.

Ordinas A, Escolar G, Cirera I, Vinas M, Cobo F, Bosch J et al. Existence of a platelet-adhesion defect in patients with cirrhosis independent of hematocrit: Studies under flow conditions. *Hepatology* 1996; 24:1137-1142.

Orvim U, Roald HE, Stephens RW, Roos N, Sakariassen KS. Tissue factor-induced coagulation triggers platelet thrombus formation as efficiently as fibrillar collagen at arterial blood flow conditions. *Arterioscler Thromb* 1994; 14(12):1976-1983.

Pagliari L, Damico G, Sorensen TIA, Lebrec D, Burroughs AK, Morabito A et al. Prevention of First Bleeding in Cirrhosis - A Meta-Analysis of Randomized Trials of Nonsurgical Treatment. *Ann Intern Med* 1992; 117:59-70.

Papadimitriou CA, Travlou A, Kalos A, Douratsos D, Lali P. Study of platelet function in patients with sickle cell anemia during steady state and vaso-occlusive crisis. *Acta Haematol* 1993; 89:180-183.

Poon MC, Demers C, Jobin F, Wu JY. Recombinant factor VIIa is effective for bleeding and surgery in patients with Glanzmann thrombasthenia. *Blood* 1999; 94(11):3951-3953.

Pytela R, Pierschbacher MD, Ginsberg MH, Plow EF, Ruoslahti E. Platelet membrane glycoprotein IIb/IIIa: member of a family of Arg-Gly-Asp--specific adhesion receptors. *Science* 1986; 231(4745):1559-1562.

Roberts HR, Monroe DM, Escobar MA. Current concepts of hemostasis - Implications for therapy. *Anesthesiology* 2004; 100(3):722-730.

Roberts HR. Recombinant factor VIIa: how safe is the stuff? *Can J Anaesth* 2005; 52(1):8-11.

Sakariassen KS, Aarts PA, de Groot PG, Houdijk WP, Sixma JJ. A perfusion chamber developed to investigate platelet interaction in flowing blood with human vessel wall cells, their extracellular matrix, and purified components. *J Lab Clin Med* 1983; 102:522-535.

Sakariassen KS, Fressinaud E, Girma JP, Baumgartner HR, Meyer D. Mediation of platelet adhesion to fibrillar collagen in flowing blood by a proteolytic fragment of human von Willebrand factor. *Blood* 1986; 67:1515-1518.

Schmidt ML, Gamerman S, Smith HE, Scott JP, DiMichele DM. Recombinant activated factor VII (rFVIIa) therapy for intracranial hemorrhage in hemophilia A patients with inhibitors. *Am J Hematol* 1994; 47(1):36-40.

Schwartz RS, Abildgaard CF, Aledort LM, Arkin S, Bloom AL, Brackmann HH et al. Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A. recombinant Factor VIII Study Group. *N Engl J Med* 1990; 323(26):1800-1805.

Spangenberg P, Redlich H, Bergmann I, Losche W, Gotzrath M, Kehrel B. The platelet glycoprotein IIb/IIIa complex is involved in the adhesion of activated platelets to leukocytes. *Thromb Haemost* 1993; 70(3):514-521.

Stassen JM, Arnout J, Deckmyn H. The hemostatic system. *Curr Med Chem* 2004; 11(17):2245-2260.

Tonda R, Galan AM, Pino M, Cirera I, Bosch J, Hernandez MR et al. Hemostatic effect of activated recombinant factor VII (rFVIIa) in liver disease: studies in an in vitro model. *J Hepatol* 2003; 39(6):954-959.

Tonda R, Galan AM, Mazzara R, White JG, Ordinas A, Escolar G. Platelet membrane fragments enhance the procoagulant effect of recombinant factor VIIa in studies with circulating human blood under conditions of experimental thrombocytopenia. *Semin Hematol* 2004a; 41(1 Suppl 1):157-162.

Tonda R, Galan AM, Pino M, Lozano M, Ordinas A, Escolar G. Hemostatic effect of activated recombinant factor VIIa in Bernard-Soulier syndrome: studies in an in vitro model. *Transfusion* 2004b; 44(12):1790-1791.

Tonda R, Lopez-Vilchez I, Galan AM, Navalon F, Pino M, Hernandez MR et al. Tissue Factor immobilized on surfaces promotes platelet adhesion and fibrin formation under flow conditions: importance of shear rate and FVIIa. En revision en *J Thromb Haemost* (2007a).

Tonda R, Lopez-Vilchez I, Pino M, Altisent C, Escolar G, Galan AM. Recombinant FVIIa (rFVIIa) improves platelet dysfunction in patients with hemophilia: studies under flow conditions with collagen-tissue factor surfaces. En revision en *Platelets* (2007b).

Toschi V, Gallo R, Lettino M, Fallon JT, Gertz SD, Fernandez-Ortiz A et al. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. *Circulation* 1997; 95(3):594-599.

Turitto VT, Weiss HJ. Red blood cells: their dual role in thrombus formation. *Science* 1980; 207:541-3 *Science*.

Valles J, Santos MT, Aznar J, Osa A, Lago A, Cosin J et al. Erythrocyte promotion of platelet reactivity decreases the effectiveness of aspirin as an antithrombotic therapeutic modality : The effect of low-dose aspirin is less than optimal in patients with vascular disease due to prothrombotic effects of erythrocytes on platelet reactivity. *Circulation* 1998; 97:350-355.

Weiss HJ, Turitto VT, Baumgartner HR. Effect of shear rate on platelet interaction with subendothelium in citrated and native blood. I. Shear dependent decrease of adhesion in von Willebrand's disease and the Bernard-Soulier syndrome. *J Lab Clin Med* 1978; 92:750-764.

Weiss HJ. Flow-related platelet deposition on subendothelium. *Thrombosis and Haemostasis* 1995; 74:117-122.

Wood WI, Capon DJ, Simonsen CC, Eaton DL, Gitschier J, Keyt B et al. Expression of active human factor VIII from recombinant DNA clones. *Nature* 1984; 312(5992):330-337.

Wu YP, de Groot PG, Sixma JJ. Shear Stress-induced detachment of blood platelets from various surfaces. *Arterios Thromb Vasc Biol* 1997; 17:3202-3207.

Wu YP, Vink T, Schiphorst M, van Zanten GH, Ijsseldijk MJ, de Groot PG et al. Platelet thrombus formation on collagen at high shear rates is mediated by von Willebrand factor-glycoprotein Ib interaction and inhibited by von Willebrand factor-glycoprotein IIb/IIIa interaction. *Arterioscler Thromb Vasc Biol* 2000; 20(6):1661-1667.

Zwaginga JJ, Sixma JJ, de Groot PG. Activation of endothelial cells induces platelet thrombus formation on their matrix. Studies of new in vitro thrombosis model with low molecular weight heparin as anticoagulant. *Arteriosclerosis* 1990; 10:49-61.

Zwaginga JJ, Ijsseldijk MJ, DE Groot PG, Kooistra M, Vos J, van Es A et al. Treatment of uremic anemia with recombinant erythropoietin also reduces the defects in platelet adhesion and aggregation caused by uremic plasma. *Thromb Haemost* 1991; 66(6):638-647.